EGFR and lung adenocarcinoma: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are one of the first examples of this therapeutic breakthrough, as they provide a greater and more sustained response in EGFR-mutated lung adenocarcinoma patients than any other existing anti-cancer therapies [5], including immunotherapies [6,7].